Home Research Developmental Therapeutics

The Developmental Therapeutics research program is focused on improving the efficacy and safety of anticancer drug therapy through the translation of basic research discoveries in childhood cancers into new treatment approaches, optimizing the use of conventional and drugs and new agents by studying their clinical pharmacology, and testing promising new agents in children with relapsed or refractory cancers.

Preclinical studies and clinical trials are ongoing with a diverse portfolio of cytotoxic and molecularly targeted anticancer drugs. We are a member institution and actively enroll patients on clinical studies from the Children’s Oncology Group’s Pediatric Phase I Consortium, New Advances in Neuroblastoma Therapy and the Pediatric Brain Tumor Consortium; we conduct industry-sponsored clinical trials of new agents; and we develop investigator-initiated clinical trials. Novel clinical trial designs with new endpoints and correlative studies focusing on the clinical pharmacokinetics and pharmacodynamics of the drugs under study are a particular interest.

Faculty

Peter C. Adamson, MD
Peter C. Adamson, MD

 

Richard Aplenc, MD, PhD
Richard Aplenc, MD, PhD

 

Rochelle Bagatell, MD
Rochelle Bagatell, MD

 

Frank Balis, MD
Frank Balis, MD

 

Elizabeth Fox, MD
Elizabeth Fox, MD

 

Yael P. Mosse, MD
Yael P. Mosse, MD

 

Peter C. Phillips, MD
Peter C. Phillips, MD